



## **MIMOSA Pro Now Offers Enhanced Usability for Tissue Health Assessment**

*A non-invasive handheld device for early intervention and improved patient outcomes*

**TORONTO/HALIFAX, CANADA, October 17, 2023 – For immediate release**

MIMOSA Diagnostics Inc. today announced updates to MIMOSA Pro, a Class II handheld skin tissue imaging device and data platform. MIMOSA Pro has been helping clinicians in the U.S. since its introduction in 2022. A refined, ergonomic design supported by a HIPAA-compliant web platform designed to improve clinician workflow is now available.

The MIMOSA Pro enables early and accurate assessment of a wide range of skin tissue issues including wound care, pressure injuries, vascular medicine, surgical, burns, and more. MIMOSA's proprietary technology allows for instant contactless capture of tissue oximetry, thermal, and digital images. These images are then securely uploaded to a web portal for remote patient monitoring and clinician collaboration towards improved patient outcomes.



Dr. Karen Cross, MIMOSA's Founder and CEO commented that "It's gratifying to see MIMOSA Pro in use at so many clinics and hospitals. As a Plastic and Reconstructive Surgeon, I recognized the potential benefit that a pocket-sized tissue imaging device like this provides. That idea is now a reality, with our technology being used on countless patients across the continuum of care. These updates, which stem from our commitment to R&D will only enhance the clinical value and help ensure that more patients have access to the assessments they need."

Dr. Matthew Regulski of The Wound Institute of Ocean County, New Jersey has been using MIMOSA Pro for 4 months and commented "I have found that the MIMOSA Pro is an invaluable tool in supporting a 'Prepare to Repair' paradigm, particularly with chronic hypoxic wounds. Not only does the MIMOSA Pro bolster my holistic approach to healing, but it provides a comprehensive roadmap of healing progression that I can readily share with my patients and colleagues. Moreover, it offers real-time validation, enabling me to gauge the positive impact of our treatment modalities. This insight empowers me to adapt patient care plans proactively, ultimately leading to improved patient outcomes."

### **About MIMOSA Diagnostics:**

MIMOSA Diagnostics Inc. is a leading provider of intuitive, equitable, and accessible healthcare technology. Their flagship product, the MIMOSA Pro is a pocket-sized imaging device that streamlines tissue health assessments for clinicians by capturing temperature, tissue oxygenation, and digital images in less than one second. The images are uploaded to a HIPAA-compliant web portal where clinicians can monitor patient progress, identify early opportunities for intervention, and collaborate towards improved patient outcomes.

To learn more about the MIMOSA Pro, visit [www.mimosadiagnostics.com](http://www.mimosadiagnostics.com).

**PR Contact:** Renée Gibbons | Marketing Manager | [renee@mimosadiagnostics.com](mailto:renee@mimosadiagnostics.com)